Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.
Back
Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer
Michael Feigin, PhD, discusses the benzodiazepines lorazepam and alprazolam and their varying impacts on progression-free survival outcomes for patients with pancreatic cancer.
Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer
Episodes
All
All
Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.
The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5